Kanāda - angļu - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (ruxolitinib phosphate) - tablet - 20mg - ruxolitinib (ruxolitinib phosphate) 20mg - antineoplastic agents

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

merz north america, inc - polidocanol (unii: 0awh8bfg9a) (polidocanol - unii:0awh8bfg9a) - polidocanol 0.01000 g in 1 ml - asclera® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. asclera has not been studied in varicose veins more than 3 mm in diameter. asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. risk summary the available data from case reports on use of polidocanol-containing products, including asclera, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. the animal reproduction studies were conducted in a manner to achieve systemic e

Kanāda - angļu - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (ruxolitinib phosphate) - tablet - 10mg - ruxolitinib (ruxolitinib phosphate) 10mg - antineoplastic agents

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

methapharm, inc - polidocanol (unii: 0awh8bfg9a) (polidocanol - unii:0awh8bfg9a) - asclera® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. asclera has not been studied in varicose veins more than 3 mm in diameter. asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. risk summary the available data from case reports on use of polidocanol-containing products, including asclera, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. the animal reproduction studies were conducted in a manner to achieve systemic e